Revolution Medicines, Inc.
RVMD • NASDAQ
Revolution Medicines, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Mark A. Goldsmith, with a market cap of $18.3B.
CEOMark A. Goldsmith
Next Earnings
Upcoming earnings announcement for Revolution Medicines, Inc.
Date
Wednesday, May 6, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$1.79
Revenue Estimate
$16.4M
Earnings History
Past 12 earnings reports for Revolution Medicines, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | Q4 2025 | -$1.86Est: -$1.56 | -19.2% | -Est: $11.6M | -100.0% |  10-K |
| Nov 5, 2025 | Q3 2025 | -$1.61Est: -$1.40 | -15.0% | -Est: $6.0M | -100.0% | 10-Q |
| Aug 6, 2025 | Q2 2025 | -$1.31Est: -$1.05 | -24.8% | -Est: $21.6M | -100.0% | 10-Q |
| May 7, 2025 | Q1 2025 | -$1.13Est: -$1.05 | -7.6% | — | — | 10-Q |
| Feb 26, 2025 | Q4 2024 | -$1.12Est: -$0.96 | -16.7% | -Est: $346.2K | -100.0% | 10-K |
| Nov 6, 2024 | Q3 2024 | -$0.94Est: $0.87 | -208.0% | -Est: $750.0K | -100.0% | 10-Q |
| Aug 7, 2024 | Q2 2024 | -$0.81Est: -$0.77 | -5.2% | -Est: $750.0K | -100.0% | 10-Q |
| May 8, 2024 | Q1 2024 | -$0.70Est: -$0.75 | +6.7% | -Est: $1.4M | -100.0% | 10-Q |
| Feb 26, 2024 | Q4 2023 | -$1.14Est: -$0.90 | -26.7% | $742.0KEst: $1.1M | -31.9% | 10-K |
| Nov 6, 2023 | Q3 2023 | -$0.99Est: -$1.01 | +2.0% | -Est: $750.0K | -100.0% | — |
| Aug 8, 2023 | Q2 2023 | -$0.92Est: -$0.81 | -13.6% | $3.8MEst: $1.6M | +145.1% | 10-Q |
| May 8, 2023 | Q1 2023 | -$0.72Est: -$0.81 | +11.1% | $7.0MEst: $2.9M | +138.6% | — |